<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title><![CDATA[Pharmacy - Newslocker]]></title><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/</link><atom:link rel="self" href="https://www.newslocker.com/en-us/profession/pharmacy_newslocker/rss/" /><atom:link rel="hub" href="http://pubsubhubbub.appspot.com" /><description><![CDATA[Find your latest Pharmacy news with just one click. Don't miss out on anything happening in your profession!]]></description><language>en-us</language><copyright>Copyright (C) 2026 newslocker.com</copyright><lastBuildDate>Fri, 17 Jul 2026 13:09:00 +0200</lastBuildDate><item><title><![CDATA[ASHP Futures 2025: What is Quiet Cracking?]]></title><description><![CDATA[Dr. Michael Wolcott defines quiet cracking and discusses how to address issues before negatively impacting the workplace.&nbsp;]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2025-what-is-quiet-cracking/</link><pubDate>Fri, 17 Jul 2026 13:09:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2025-what-is-quiet-cracking/</guid></item><item><title><![CDATA[As Medicare’s GLP-1 Bridge Program Launches, ISMP Offers Guidance for Pharmacists]]></title><description><![CDATA[Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzMedicare&rsquo;s new Bridge program, which launched on July 1,makes available certain glucagon-like peptide-1 receptor agonist (GLP-1) drugs for a $50 copay, which is hundreds less than the current cash prices for patients not covered for the drugs by insurance.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%;]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/as-medicares-glp-1-bridge-program-launches-ismp-offers-guidance-for-pharmacists/</link><pubDate>Mon, 13 Jul 2026 14:43:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/as-medicares-glp-1-bridge-program-launches-ismp-offers-guidance-for-pharmacists/</guid></item><item><title><![CDATA[Omadacycline Trial Offers a Rare Win for NTM, While Shorter TB Treatment Regimens Are Limited by Toxicities]]></title><description><![CDATA[By Gina ShawOmadacycline monotherapy cleared Mycobacterium abscessus from the sputum of 53.8% of patients by day 84 of a phase 2 clinical trial, compared with 25% on placebo, offering the first randomized evidence that a single oral drug can reduce the bacterial burden of a nontuberculous mycobacterial (NTM) infection (Clin Infect Dis 2026 March 3. doi:10.1093/cid/ciag062).figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }fig]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/omadacycline-trial-offers-a-rare-win-for-ntm-while-shorter-tb-treatment-regimens-are-limited-by-toxicities/</link><pubDate>Wed, 08 Jul 2026 18:40:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/omadacycline-trial-offers-a-rare-win-for-ntm-while-shorter-tb-treatment-regimens-are-limited-by-toxicities/</guid></item><item><title><![CDATA[Rethinking Inpatient IV Default for PWID With Serious Injection-Related Infections]]></title><description><![CDATA[By Gina ShawPatient-directed discharge without an oral antibiotic doubles 90-day readmission risk among people who inject drugs (PWID) with serious injection-related infections, Ellen Eaton, MD, MSPH, a professor in the Department of Psychiatry and Medicine at the University of Alabama at Birmingham, told attendees at the newly combined Making a Difference in Infectious Diseases and Society of Infectious Diseases Pharmacists 2026 meeting, in Orlando, Florida.figure { display:inline-block; margin]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/rethinking-inpatient-iv-default-for-pwid-with-serious-injection-related-infections/</link><pubDate>Wed, 08 Jul 2026 18:28:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/rethinking-inpatient-iv-default-for-pwid-with-serious-injection-related-infections/</guid></item><item><title><![CDATA[ASHP Futures 2026: Tips for Hazardous Drug Wipe Sampling]]></title><description><![CDATA[.secondwrap{font-family:Roboto !important;border:1px solid #a6a6a6;margin-bottom:10px}.secondcontainer{margin-bottom:10px;padding:0px !important}.container-fluid{max-width:1140px;margin-right:auto;margin-left:auto}.ra-img{padding-top:5px;width:80px;height:80px;margin-left:1rem!important}.title{font-size:0.9375rem;font-weight:500;line-height:21px;margin:0px !important}.text{font-size:0.9375rem;line-height:21px;padding-top:5px;padding-bottom:5px;margin:0px}*,::after,::before{box-sizing:border-box}]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-tips-for-hazardous-drug-wipe-sampling/</link><pubDate>Wed, 08 Jul 2026 11:27:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-tips-for-hazardous-drug-wipe-sampling/</guid></item><item><title><![CDATA[Adult AML Survivors Face Heightened Risk for Additional Cancers]]></title><description><![CDATA[Originally published by our sister publication Specialty Pharmacy ContinuumBy Cynthia E. KeenAdult acute myeloid leukemia (AML) survivors have a significantly higher risk of developing a second primary cancer in their lifetime compared with the general population, according to data presented at the 2026 ASCO Annual Meeting, in Chicago (abstract 11070). Adults younger than 59 years of age have the highest risk levels (standardized incidence ratio [SIR], 1.91), with higher measures in men (1.37) t]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/adult-aml-survivors-face-heightened-risk-for-additional-cancers/</link><pubDate>Tue, 07 Jul 2026 19:25:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/adult-aml-survivors-face-heightened-risk-for-additional-cancers/</guid></item><item><title><![CDATA[Pediatric Iron Deficiency: New Ferritin Thresholds, and a Wider Role for Pharmacy]]></title><description><![CDATA[figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }vector juice &ndash; stock.adobe.com.By Gina ShawPediatric iron deficiency is being redefined, with significant practical implications for clinicians]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/pediatric-iron-deficiency-new-ferritin-thresholds-and-a-wider-role-for-pharmacy/</link><pubDate>Tue, 07 Jul 2026 18:26:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/pediatric-iron-deficiency-new-ferritin-thresholds-and-a-wider-role-for-pharmacy/</guid></item><item><title><![CDATA[IV Iron During Acute Infection Linked to Lower Mortality, Real-World Analysis Finds]]></title><description><![CDATA[figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }Iron IV: anna &ndash; stock.adobe.com.By Gina ShawHospitalized adults with iron deficiency anemia (IDA) and an acute bacterial infection who received]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/iv-iron-during-acute-infection-linked-to-lower-mortality-real-world-analysis-finds/</link><pubDate>Tue, 07 Jul 2026 18:21:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/iv-iron-during-acute-infection-linked-to-lower-mortality-real-world-analysis-finds/</guid></item><item><title><![CDATA[Action Steps for Reimbursement Readiness]]></title><description><![CDATA[Bonnie Kirschenbaum, MS, FASHP,FCSHP&ldquo;Reimbursement Matters&rdquo; is a tool for maintaining your health system&rsquo;s fiscal health. Please email the author at bonniekirschenbaum@gmail.com with suggestions on reimbursement issues that you would like to see covered.Financial stability remains a critical concern as healthcare organizations navigate 2026 and prepare for fiscal year (FY) 2027, which begins Oct. 1, 2026, for inpatient settings. Calendar year 2027 follows for all other sites of]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/action-steps-for-reimbursement-readiness/</link><pubDate>Mon, 06 Jul 2026 17:38:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/action-steps-for-reimbursement-readiness/</guid></item><item><title><![CDATA[FcRn Inhibition As a Therapeutic Class]]></title><description><![CDATA[Originally published by our sister publication Specialty Pharmacy ContinuumAmy E. Clarke, DNP, RN, IgCN&reg;Chief Clinical OfficerImmunoglobulin National SocietyCalabasas, CaliforniaLuba Sobolevsky, PharmD, IgCP&reg;President and CEOImmunoglobulin National SocietyCalabasas, CaliforniaThe treatment landscape for immunoglobulin G (IgG)-mediated autoimmune disease is undergoing a significant shift toward mechanism-driven therapeutics. Management has relied on broad immunosuppression, including cort]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/fcrn-inhibition-as-a-therapeutic-class/</link><pubDate>Mon, 06 Jul 2026 14:27:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/fcrn-inhibition-as-a-therapeutic-class/</guid></item><item><title><![CDATA[Compassionate-Use Antifungals: What Clinicians Can Almost Access Now]]></title><description><![CDATA[Originally published by our sister publication Infectious Disease Special EditionBy Gina ShawDespite decades of need, antifungal drug development has produced relatively few mechanistically novel agents. Clinicians treating invasive fungal infections continue to rely on three primary classes&mdash;azoles, echinocandins, and polyenes&mdash;targeting just two major pathways.&ldquo;We&rsquo;re actually pretty good at making antifungals. What we struggle with is making good antifungals that are not]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/compassionate-use-antifungals-what-clinicians-can-almost-access-now/</link><pubDate>Mon, 06 Jul 2026 11:37:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/compassionate-use-antifungals-what-clinicians-can-almost-access-now/</guid></item><item><title><![CDATA[Emerging Therapies  For Blood Cancers]]></title><description><![CDATA[Christie Denton, PharmD, BCPSClinical Assistant Professor/Drug Information SpecialistUniversity of Illinois at Chicago College of PharmacyLeukemia, lymphoma, and myeloma, the 3 main types of blood cancers, account for about 10% of new cancer diagnoses each year.1 In 2024, 187,740 new cases of leukemia, lymphoma, and myeloma were estimated to be diagnosed, with approximately 57,260 deaths expected. Advances in treatment for blood cancers have led to guideline updates, expanded indications for sev]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/emerging-therapies-for-blood-cancers/</link><pubDate>Thu, 02 Jul 2026 19:03:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/emerging-therapies-for-blood-cancers/</guid></item><item><title><![CDATA[ASHP Futures 2025: Medication Safety in the AI Era]]></title><description><![CDATA[Drs. Sylvia Stoffella and Ben Michaels discuss the potential of their AI pilot project to improve patient safety and assist workflows.&nbsp;]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2025-medication-safety-in-the-ai-era/</link><pubDate>Tue, 30 Jun 2026 12:53:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2025-medication-safety-in-the-ai-era/</guid></item><item><title><![CDATA[A Plague on Patient Assistance]]></title><description><![CDATA[Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawAutumn Zuckerman,PharmDA 34-year-old man with stage IV colorectal cancer was responding to treatment when his insurer abruptly stopped covering his medication. What followed consumed five months, required him to obtain a passport, submit to a telehealth visit with a foreign physician he had never met, and ultimately receive his medication from an international pharmacy.The specialty pharmacy team spent roughly]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/a-plague-on-patient-assistance/</link><pubDate>Tue, 23 Jun 2026 13:47:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/a-plague-on-patient-assistance/</guid></item><item><title><![CDATA[Decnupaz Approved for Blastic Plasmacytoid Dendritic Cell Neoplasms]]></title><description><![CDATA[Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHA new treatment option, pivekimab sunirine-pvzy (Decnupaz, AbbVie), has been approved for blastic plasmacytoid dendritic cell neoplasm, a rare type of hematologic malignancy.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:trans]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/decnupaz-approved-for-blastic-plasmacytoid-dendritic-cell-neoplasms/</link><pubDate>Tue, 23 Jun 2026 13:44:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/decnupaz-approved-for-blastic-plasmacytoid-dendritic-cell-neoplasms/</guid></item><item><title><![CDATA[ASHP Futures 2026: Proactive Tools to Modernize Medication Safety]]></title><description><![CDATA[Dr. Sondra May shares key insights from the 2026 ASHP Pharmacy Forecast and details how shifting from reactive event tracking to a proactive system design will positively impact patient safety.&nbsp;]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-proactive-tools-to-modernizemedicationsafety/</link><pubDate>Mon, 22 Jun 2026 11:28:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-proactive-tools-to-modernizemedicationsafety/</guid></item><item><title><![CDATA[As Manufacturers Catch On to Alternative Funding Programs, More Specialty Patients Routed to Overseas Pharmacies]]></title><description><![CDATA[figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }McMahon PublishingMore drug manufacturers are identifying and rejecting alternative funding program (AFP) applications, pushing commerically insured]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/as-manufacturers-catch-on-to-alternative-funding-programs-more-specialty-patients-routed-to-overseas-pharmacies/</link><pubDate>Thu, 18 Jun 2026 13:39:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/as-manufacturers-catch-on-to-alternative-funding-programs-more-specialty-patients-routed-to-overseas-pharmacies/</guid></item><item><title><![CDATA[Ambulatory Care Pharmacists Drive Higher Specialty Prescription Capture]]></title><description><![CDATA[figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:block; }figcaption { padding:5px; background:transparent; word-wrap:normal; text-align:center; font-size:10px; line-height:12px; }.figure-wrapper { text-align:center; }pikselstock-stock.adobe.comBy Gina ShawAmbulatory care pharmacists at Yale New Haven Health (YNHH) kept two-thirds of the specialty prescriptions the]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ambulatory-care-pharmacists-drive-higher-specialty-prescription-capture/</link><pubDate>Thu, 18 Jun 2026 13:37:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ambulatory-care-pharmacists-drive-higher-specialty-prescription-capture/</guid></item><item><title><![CDATA[ASHP Calls on HHS to Halt Lilly’s 340B Data Cutoff]]></title><description><![CDATA[Editor's note: Updated 6/18 to reflect cut-off date not yet enacted, plus new comments from Jesse Dresser, Esq., of Frier LevittBy Gina ShawIn early June, Eli Lilly gave an initial group of 340B hospitals five business days to turn over detailed claims-level data or lose access to discounted drug pricing, and ASHP is urging federal regulators to step in before the deadline hit.As of mid-June, the threatened cutoff had not taken effect for many of the covered entities that received the notice, ev]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-calls-on-hhs-to-halt-lillys-340b-data-cutoff/</link><pubDate>Thu, 18 Jun 2026 12:01:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-calls-on-hhs-to-halt-lillys-340b-data-cutoff/</guid></item><item><title><![CDATA[ASHP Futures 2026: Recognizing Progress in Precepting]]></title><description><![CDATA[This year at ASHP Futures, Dr. Ted Morton received the ASHP Foundation 2025 Pharmacy Residency Excellence Preceptor Award for his over-three decade career in progressing the evolution of pharmacy precepting practices. In this interview with PPN, Dr. Morton discusses what the recognition means to him and shares some of the important lessons and tips he&rsquo;s learned on how to effectively improve pharmacy residency precepting and training programs.&nbsp;]]></description><link>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-recognizing-progress-in-precepting/</link><pubDate>Thu, 18 Jun 2026 11:21:00 +0200</pubDate><guid>https://www.newslocker.com/en-us/profession/pharmacy_newslocker/ashp-futures-2026-recognizing-progress-in-precepting/</guid></item></channel></rss>